We are live on ! Find out more

Orthofix Medical

OFIX

Market cap $290M

7.12 USD

-0.78

9.87%

At close Updated Nov 10, 4:00 PM EST

Pre-market

After hours

7.12

0.00

0%

1 day

-9.87%

5 days

-21.41%

1 month

-23.28%

3 months

-30.6%

6 months

-38.99%

Year to date

-52.02%

1 year

-52.63%

5 years

-78.5%

10 years

-80.7%

About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.

Employees: 1,605

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 70%

Negative 10%

Orthofix Medical Q3 Earnings Call Highlights

Orthofix Medical NASDAQ: OFIX lowered its 2026 outlook after third-quarter results fell short of management's expectations, as softer U.S. spine procedure volumes and supplier delays constrained its ability to support demand.

Orthofix Medical Q3 Earnings Call Highlights

Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Orthofix (OFIX) Surpasses Q3 Earnings Estimates

Orthofix (OFIX) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.2 per share a year ago.

Orthofix (OFIX) Surpasses Q3 Earnings Estimates

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines. Third Quarter 2026 Highlights Total reported net sales of $207.9 million, representing an increase of 1% on a reported b.

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Zacks Investment Research

Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?

Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?

Orthofix to Report Third Quarter 2026 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November 9, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing 833-461-5787 in the U.S., and 585-542-9983 in all other locations, and referencing th.

Orthofix to Report Third Quarter 2026 Financial Results

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

See News Rankings

Price charts implemented using Lightweight Charts™